$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000154422717000007 Filed on May 09, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$84.00K	$63.00K	$146.0K
YoY Change	-55.56%	-56.85%	873.33%
Cost Of Revenue	$274.0K	$269.0K	$1.176M
YoY Change	-77.78%	-77.13%	3260.0%
Gross Profit	-$190.0K	-$206.0K	-$1.030M
YoY Change	-81.8%	-80.0%	5050.0%
Gross Profit Margin	-226.19%	-326.98%	-705.48%
Selling, General & Admin	$10.75M	$7.129M	$14.45M
YoY Change	-4.09%	-50.68%	30.85%
% of Gross Profit
Research & Development	$4.997M	$5.764M	$5.955M
YoY Change	-16.54%	-3.21%	3.62%
% of Gross Profit
Depreciation & Amortization	$500.0K	$500.0K	$504.0K
YoY Change	-16.67%	-0.79%	122.03%
% of Gross Profit
Operating Expenses	$18.01M	$14.65M	$21.59M
YoY Change	-2.26%	-32.13%	28.27%
Operating Profit	-$17.93M	-$14.59M	-$21.44M
YoY Change	-1.7%	-31.96%	27.51%
Interest Expense	-$270.0K	-$240.0K	-$220.0K
YoY Change	3.85%	9.09%	-48.84%
% of Operating Profit
Other Income/Expense, Net	$25.00K	-$60.00K	-$27.00K
YoY Change	-213.64%	122.22%	-179.41%
Pretax Income	-$18.17M	-$14.89M	-$21.68M
YoY Change	-1.86%	-31.35%	26.02%
Income Tax	$13.00K	$9.000K	$75.00K
% Of Pretax Income
Net Earnings	-$18.19M	-$14.90M	-$21.76M
YoY Change	-2.06%	-31.54%	26.46%
Net Earnings / Revenue	-21650.0%	-23642.86%	-14902.74%
Basic Earnings Per Share
Diluted Earnings Per Share	-$113.70	-$93.12	-$181.30
COMMON SHARES
Basic Shares Outstanding	35.66M shares	35.64M shares	27.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.60M	$99.10M	$110.1M
YoY Change	-41.37%	-9.99%	-34.97%
Cash & Equivalents	$22.94M	$25.43M	$20.48M
Short-Term Investments	$63.60M	$73.70M	$89.60M
Other Short-Term Assets	$2.500M	$2.000M	$2.600M
YoY Change	0.0%	-23.08%	30.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$89.09M	$101.2M	$112.7M
YoY Change	-40.65%	-10.28%	-34.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.956M	$4.707M	$8.667M
YoY Change	-51.45%	-45.69%	106.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$215.0K
YoY Change		-100.0%	7.5%
Other Assets	$23.00K	$23.00K	$400.0K
YoY Change	0.0%	-94.25%	300.0%
Total Long-Term Assets	$4.791M	$5.169M	$9.321M
YoY Change	-44.36%	-44.54%	107.13%
TOTAL ASSETS
Total Short-Term Assets	$89.09M	$101.2M	$112.7M
Total Long-Term Assets	$4.791M	$5.169M	$9.321M
Total Assets	$93.89M	$106.3M	$122.1M
YoY Change	-40.85%	-12.9%	-30.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.275M	$2.384M	$4.218M
YoY Change	32.81%	-43.48%	68.72%
Accrued Expenses	$9.000K	$8.000K	$7.600M
YoY Change	-99.89%	-99.89%	85.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.82M	$10.59M	$11.81M
YoY Change	10.05%	-10.3%	78.89%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$925.0K	$1.006M	$1.400M
YoY Change	-33.93%	-28.14%	1300.0%
Total Long-Term Liabilities	$925.0K	$1.006M	$1.400M
YoY Change	-33.93%	-28.14%	1300.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.82M	$10.59M	$11.81M
Total Long-Term Liabilities	$925.0K	$1.006M	$1.400M
Total Liabilities	$12.74M	$11.60M	$13.22M
YoY Change	4.76%	-12.25%	97.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$283.6M	-$265.4M	-$189.7M
YoY Change	36.19%	39.92%
Common Stock	$36.00K	$36.00K	$27.00K
YoY Change	0.0%	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$81.14M	$94.72M	$108.8M
YoY Change
Total Liabilities & Shareholders Equity	$93.89M	$106.3M	$122.1M
YoY Change	-40.85%	-12.9%	-30.57%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$18.19M	-$14.90M	-$21.76M
YoY Change	-2.06%	-31.54%	26.46%
Depreciation, Depletion And Amortization	$500.0K	$500.0K	$504.0K
YoY Change	-16.67%	-0.79%	122.03%
Cash From Operating Activities	-$12.09M	-$15.19M	-$15.41M
YoY Change	-24.06%	-1.46%	7.06%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$75.00K	$370.0K
YoY Change	-96.0%	-79.73%	-4.88%
Acquisitions
YoY Change
Other Investing Activities	$10.00M	-$3.240M	-$6.970M
YoY Change	-73.53%	-53.52%	-138.13%
Cash From Investing Activities	$9.970M	-$3.312M	-$7.336M
YoY Change	-73.26%	-54.85%	-141.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$0.00	$0.00
YoY Change	-100.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-12.09M	-$15.19M	-$15.41M
Cash From Investing Activities	9.970M	-$3.312M	-$7.336M
Cash From Financing Activities	0.000	$0.00	$0.00
Net Change In Cash	-2.120M	-$18.50M	-$22.75M
YoY Change	-102.81%	-18.68%	-117.73%
FREE CASH FLOW
Cash From Operating Activities	-$12.09M	-$15.19M	-$15.41M
Capital Expenditures	$20.00K	$75.00K	$370.0K
Free Cash Flow	-$12.11M	-$15.26M	-$15.78M
YoY Change	-26.25%	-3.3%	6.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2000	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35662124	shares
CY2017Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2016Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1000	USD
CY2017Q1	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1000	USD
CY2016Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	1000	USD
CY2017Q1	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	0	USD
CY2016Q4	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	1000	USD
CY2017Q1	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	0	USD
CY2017Q1	ovas	Numberof Treatments NumberofTreatments	1	treatment
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
CY2017Q1	ovas	Potential Treatments In Development PotentialTreatmentsInDevelopment	2	treatment
CY2016Q4	ovas	Restructuringand Related Cost Expected Numberof Positions Eliminated Percent RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent	0.30
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2183000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2384000	USD
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11026000	USD
CY2017Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8207000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3620000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4272000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-60000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-59000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	358419000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	360145000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	295000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	27000	USD
CY2016Q4	us-gaap	Assets Assets	122543000	USD
CY2017Q1	us-gaap	Assets Assets	106319000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	116444000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	101150000	USD
CY2017Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	500000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	114388000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	99102000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	63000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	62000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	114448000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	99161000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	46600000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	41500000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	1700000	USD
CY2016Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	21	security
CY2017Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	18	security
CY2017Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	19	security
CY2017Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	1	security
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43224000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20478000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43930000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25433000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	99100000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35641505	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35662124	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35641505	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35662124	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21595000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14894000	USD
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	1176000	USD
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	269000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	504000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	461000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4000	USD
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	65000	USD
CY2017Q1	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21683000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14886000	USD
CY2016Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-391000	USD
CY2017Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-421000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	378000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	184000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	721000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3239000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-470000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-458000	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-88000	USD
CY2017Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2016Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	174000	USD
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	182000	USD
CY2016Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	38000	USD
CY2017Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	38000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	14325000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	11597000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122543000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106319000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13209000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10591000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-22746000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-18497000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7336000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3312000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15410000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15185000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-21758000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-14895000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	21585000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	14650000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-21439000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14587000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	163000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1116000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1006000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-27000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-60000	USD
CY2017Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	2208000	USD
CY2017Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	2200000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	3300000	USD
CY2016Q1	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	800000	USD
CY2016Q1	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	750000	USD
CY2017Q1	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	0	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	370000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	75000	USD
CY2016Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	27118000	USD
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	26562000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2056000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2048000	USD
CY2016Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	20814000	USD
CY2017Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	23325000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9192000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8979000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5572000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4707000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5955000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5764000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	439000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	439000	USD
CY2016Q1	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	1500000	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	1488000	USD
	us-gaap	Restructuring Costs RestructuringCosts	6900000	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	3406000	USD
CY2017Q1	us-gaap	Restructuring Reserve RestructuringReserve	2626000	USD
CY2017Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	2600000	USD
CY2017Q1	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	60000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-250177000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-265400000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-265400000	USD
CY2016Q1	us-gaap	Revenues Revenues	146000	USD
CY2017Q1	us-gaap	Revenues Revenues	63000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14454000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7129000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3551000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1360000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.27
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.20
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1030650	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1832250	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.56
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.58
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	70458000	USD
CY2017Q1	us-gaap	Short Term Investments ShortTermInvestments	73669000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	108218000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	94722000	USD
CY2017Q1	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.5
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27301000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35642000	shares
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with U.S. GAAP, which require management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001544227-17-000007-index-headers.html	Edgar Link	pending
0001544227-17-000007-index.html	Edgar Link	pending
0001544227-17-000007.txt	Edgar Link	pending
0001544227-17-000007-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ovas-20170331.xml	Edgar Link	completed
ovas-20170331.xsd	Edgar Link	pending
ovas-20170331x10q.htm	Edgar Link	pending
ovas-20170331xex311.htm	Edgar Link	pending
ovas-20170331xex312.htm	Edgar Link	pending
ovas-20170331xex321.htm	Edgar Link	pending
ovas-20170331xex322.htm	Edgar Link	pending
ovas-20170331_cal.xml	Edgar Link	unprocessable
ovas-20170331_def.xml	Edgar Link	unprocessable
ovas-20170331_lab.xml	Edgar Link	unprocessable
ovas-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2017 Q2 Form 10-Q Financial Statement

#000154422717000007 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2017 Q2 Form 10-Q Financial Statement

#000154422717000007 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst